The cost of growing old is rising faster than incomes across advanced economies, a shift now measurable in household budgets and public balance sheets. In the United States, an AARP Public Policy Institute study found that long-term care expenses jumped nearly 50 percent between 2019 and 2024, pushing middle-class families toward unpaid family labour or depleted savings. German insurers report that nursing-home residents paid an average of €3,364 per month out of pocket in their first year, a €256 increase from the previous year. The demographic arithmetic behind these numbers is unforgiving: the global over-60 population is projected to reach 1.4 billion by 2030, and the OECD calculates that member states would need to expand their long-term care workforces by more than 60 percent by 2040 just to maintain current caregiver-to-patient ratios.

In response, technology developers are training artificial intelligence on the body’s electrical signals and placing companion machines inside homes. The Israeli start-up Hemispheric has built an AI model, Descartes, trained on 250,000 hours of EEG recordings from over 100,000 participants. The model, which contains six billion parameters, aims to translate complex brain activity into clinically readable information for diagnosing depression, PTSD, Parkinson’s disease and early cognitive decline. The company has raised $52 million and currently supplies its platform to pharmaceutical researchers; it has not yet received regulatory clearance for use in doctors’ offices. Separately, a global market for elder-care robots—ranging from talking dolls in Seoul to humanoid assistants in Chinese care homes—exceeded $3.1 billion in 2025 and is forecast to reach nearly $13 billion by 2035. Italian government projections indicate the country will need at least 200,000 additional caregivers by 2040, a gap robotics firms are explicitly targeting.

Alongside these clinical and robotic tools, a consumer longevity industry markets therapies that frequently lack human evidence. At a New York biohacking conference, vendors offered ozone treatments, hydrogen inhalations and IV infusions of NAD+, a coenzyme that endocrinologists describe as a waste of money for healthy people. A West Hollywood wellness chain sells plasma exchange and hyperbaric oxygen to a clientele it describes as mostly fit and well, promising to “make your health span match your life span.” The contrast between this commercial activity and regulated medical research is sharp, and it is drawing scrutiny from clinicians who note that very few of the interventions have been validated in controlled human trials.

For households, the financial strain is already reshaping retirement decisions. A US family depleted its savings fighting insurance denials before accessing Medicaid; the only remaining income is Social Security. In Australia, financial advisers field questions from parents considering delaying retirement to cover university fees so their children avoid large debts, and from couples weighing a home upgrade against the risk of outliving their superannuation. The AARP has lobbied Washington for a family caregiver tax credit for a decade, but the measure remains stalled. The next concrete milestone arrives in low-Earth orbit: the US Federal Communications Commission has approved Reflect Orbital’s plan to launch a satellite with movable mirrors to reflect sunlight onto solar farms after dark, a venture that has raised $28 million but whose economics remain unproven.